Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Documentation in Long-Term and Home Healthcare Setting

Documentation in Long-Term and Home Healthcare Setting

Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities

Guidelines for Nursing Documentation II

Guidelines for Nursing Documentation II

Effective documentation is an integral part of nursing practice. Here are some essential guidelines to follow when documenting patient care:
Timely documentation is crucial to ensure continuity of care for patients. Any delays in recording or reporting medical information can result in medical errors and even adverse patient outcomes. From medication administration to diagnostic test results, every detail must be accurately and promptly documented to provide the best possible care for patients.

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Polygenic risk for psychiatric disorders and its association with neuropsychiatric symptoms in dementia.

International review of psychiatry (Abingdon, England)·2025

Same author

CSF biomarkers of neuroinflammation are associated with regional atrophy.

Journal of neurology·2025

Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Technology and Dementia Preconference.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Search research articles

Related Experiment Video

Updated: Jul 29, 2025

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test

Published on: November 23, 2019

[The German S3 guidelines on dementia].

Frank Jessen^1,2, Lara Bohr³, Christopher Kruse⁴

¹Klinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. frank.jessen@uk-koeln.de.

|May 26, 2023

Summary

This summary is machine-generated.

A new S3 guideline for dementia care in Germany is being developed, addressing increasing patient numbers and recent advancements in Alzheimer's disease diagnosis and treatment. This living guideline will be digitally accessible, incorporating modifiable risk factors and prevention strategies.

Keywords:

Alzheimer’s disease Living guidelines Mild cognitive impairment Prevention Risk factors

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients

Published on: February 6, 2021

Related Experiment Videos

Last Updated: Jul 29, 2025

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test

Published on: November 23, 2019

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients

Published on: February 6, 2021

Area of Science:

Neurology
Geriatrics
Public Health

Context:

Rising dementia patient numbers in Germany necessitate updated care guidelines.
Previous S3 guidelines (2008, 2016) require revision due to significant advancements.
The German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) and the German Association for Neurology (DGN) coordinate the guideline development.

Purpose:

To provide an updated S3 guideline for comprehensive dementia care.
To incorporate recent diagnostic breakthroughs, including mild cognitive impairment (MCI) in Alzheimer's disease.
To integrate emerging disease-modifying therapies and emphasize prevention strategies.

Summary:

The guideline update reflects new diagnostic criteria for Alzheimer's disease, including MCI.
It anticipates the availability of causal, disease-modifying treatments.
Epidemiological data highlighting 40% modifiable dementia risk factors underscore the importance of prevention.

Impact:

The updated guideline will be digitally available as an app for accessibility.
It will function as a living guideline, allowing for rapid updates.
This ensures timely integration of future research and clinical practice advancements in dementia care.